MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$1,751K
EPS
-$0.06
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
2,788
1,607
2,050*
2,964
General and administrative
7,352
6,830
6,010*
4,378
Total operating expenses
10,140
8,437
8,060
7,342
Loss from operations
-10,140
-8,437
-8,060*
-7,342
Interest income
441
394
362*
279
Interest expense
-
-
29*
15
Change in fair value of warrant liability
-7,977
4,780
141*
-1,067
Total other income (expenses)
8,418
-4,386
192*
1,331
Net loss
-1,722
-12,823
-7,869*
-6,011
Unrealized loss on marketable securities, net
-29
-1
0*
-
Net loss attributable to common stockholders
-
-
-
-6,011
Net comprehensive loss
-1,751
-12,824
-7,869
-
Basic EPS
-0.06
-0.54
-0.455
-0.33
Diluted EPS
-0.06
-0.54
-0.455
-0.33
Basic Average Shares
26,917,266
23,908,153
17,293,180
18,065,389
Diluted Average Shares
26,917,266
23,908,153
17,293,180
18,065,389
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net comprehensive
loss
-$1,751K
Change in fair value of
warrant liability
-$7,977K
(-2032.89%↓ Y/Y)
Interest income
$441K
(184.52%↑ Y/Y)
Net loss
-$1,722K
(73.29%↑ Y/Y)
Unrealized loss on
marketable securities, net
-$29K
Total other income
(expenses)
$8,418K
(1531.40%↑ Y/Y)
Loss from operations
-$10,140K
(-45.63%↓ Y/Y)
Total operating
expenses
$10,140K
(45.63%↑ Y/Y)
General and
administrative
$7,352K
(41.03%↑ Y/Y)
Research and development
$2,788K
(59.31%↑ Y/Y)
Buy us a coffee
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)